Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma

Table 1

Patient characteristics and clinical data.

	All patients				Patients without glucocorticoid use before rituximab infusion
	All	IRR grades 0 and 1	IRR grades 2–4	p value	All	IRR grades 0 and 1	IRR grades 2–4	p value
Number of Pts	127	84	43		96	58	38
Age (mean (SD))	71.7 (11.0)	71.3 (11.2)	72.3 (10.4)	0.63	72.6 (10.6)	72.1 (10.5)	73.2 (10.6)	0.66
Gender
Male	69	46	23	⁺0.89	47	29	18	⁺0.80
Female	58	38	20		49	29	20
Histopathology
DLBCL	98	69	29	⁺0.062	70	45	25	⁺0.20
Indolent lymphoma^(a–f)	29	15	14		26	13	13
FL^(a)	17	10	7		16	10	6
LPL/WM^(b)	4	2	2		4	2	2
MCL^(c)	3	1	2		2	0	2
SLL^(d)	2	0	2		2	0	2
SMZL^(e)	2	1	1		1	0	1
MALT^(f)	1	1	0		1	1	0
Ann Arbor staging
I/II	57	44	13	⁺0.018	47	35	12	⁺0.0058
III/IV	70	40	30		49	23	26
ECOG PS
2 or more	108	71	37	⁺0.82	10	5	5	^‡0.51
0, 1	19	13	6		86	53	33
sIL-2R (U/mL)
>2000	33	24	9	⁺0.74	18	12	6	⁺0.94
≤2000	79	55	24		67	44	23
LDH (U/L)
>ULN	58	37	21	⁺0.61	36	18	18	⁺0.11
≤ULN	69	47	22		60	40	20
Hemoglobin (g/dL)
>10	102	67	35	⁺0.83	79	50	29	⁺0.21
≤10	25	17	8		17	8	9
Bone marrow infiltration
Present	26	11	15	⁺0.004	19	5	14	⁺0.0007
Absent	101	73	28		77	53	24
Splenomegaly
Present	17	8	9	⁺0.074	9	3	6	^‡0.149
Absent	110	76	34		87	55	32
B symptoms
Present	17	12	5	⁺0.68	4	1	3	^‡0.30
Absent	110	72	38		92	57	35
Bulky mass
Present	9	6	3	^‡1.0	9	6	3	^‡1.0
Absent	118	78	40		87	52	35
Circulating lymphoma cells (/μl)
>25000	1	0	1	^‡0.34	1	0	1	^‡0.40
≤25000	126	84	42		95	58	37
Number of previous chemotherapy regimens
0	127	84	43	^‡1.0	96	58	38	^‡1.0
≥1	0	0	0		0	0	0
Glucocorticoid use before rituximab infusion
Present	31	26	5	⁺0.016	—	—	—
Absent	96	58	38		—	—	—

Statistical analysis, t-test, ^⁺chi-square test, and ^‡Fisher’s exact test. IRRs: infusion-related reactions; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; MALT: mucosa-associated lymphoid tissue lymphoma; LPL: lymphoplasmacytic lymphoma; WM: Waldenström macroglobulinemia; SLL: small lymphocytic lymphoma; SMZL: splenic marginal zone lymphoma; sIL-2R: serum interleukin-2 receptor; LDH: lactate dehydrogenase; ULN: upper limit of the normal range; ECOG PS: Eastern Cooperative Oncology Group performance status score; SD: standard deviation; Pts: patients. Indolent lymphoma was composed of FL, LPL/WM, MCL, SLL, SMZL, and MALT.